Kapağı yeniden konumlandırmak için sürükleyin
Resimler
Hakkımızda
A pivotal development for U.S. patients in 2026 is the Fourth Temporary Extension of telemedicine flexibilities regarding controlled substances. In January 2026, the Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) jointly announced that the ability for registered practitioners to prescribe Schedule II-V controlled substances via telemedicine has been officially extended through December 31, 2026. This extension serves as a vital bridge, ensuring that patients—including seniors and those with chronic disabilities—can continue accessing necessary care while permanent federal regulations are finalized.
Avatarını kırp
